U.S. Insights: Trends in First-to-File NCE-1 ANDAs Based on Peak Estimated Brand Drug Sales

IPD Analytics has released a Trend Report as part of our NEW Data STACK subscription that evaluates the relationship between first-to-file NCE−1 ANDAs and peak sales of brand drugs. In the report, we analyzed a total of 263 first-to-file ANDAs since January 2019 to evaluate the correlation between ANDA filings and peak annual sales volume of the referenced brand drugs.

Our experts leverage the datasets housed within Data STACK to draw insight from stats, trends, analogs, and company profiles to develop Trend Reports that provide a deep dive into pipeline dynamics, approvals, litigation, sales, pricing, rebates, formulary trends, and market access metrics. Dive into the data and insights now.